Spots Global Cancer Trial Database for metastatic prostate cancer
Every month we try and update this database with for metastatic prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel | NCT01814150 | Metastatic Lung... Metastatic Brea... Metastatic Gast... Metastatic Pros... Metastatic Blad... | 18 Years - | Meir Medical Center | ||
| Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer | NCT01560923 | Metastatic Pros... | Indoximod Sipuleucel-T Placebo | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes | NCT06439225 | Metastatic Cast... Metastatic Pros... | Docetaxel Carboplatin | 18 Years - | Canadian Cancer Trials Group | |
| Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) | NCT00684970 | Metastatic Cast... | Hamsa-1™ TL-118 | 18 Years - | Tiltan Pharma Ltd. | |
| Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer | NCT03230734 | Metastatic Cast... | Radium-223 Docetaxel | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer | NCT00494338 | Metastatic Pros... | Docetaxel | 18 Years - | Sanofi | |
| PROState Pathway Embedded Comparative Trial | NCT04400656 | Prostate Cancer Non-metastatic ... Metastatic Pros... Prostate Adenoc... Metastatic Pros... Prostate Cancer... | 18 Years - | Imperial College London | ||
| A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 | NCT02916537 | Prostate Cancer | CTT1057 Prostatectomy | 18 Years - | Cancer Targeted Technology | |
| Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | NCT04332744 | Metastatic Pros... | Enzalutamide Talazoparib | 18 Years - | MedSIR | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| Pazopanib, Docetaxel, Prednisone Prostate | NCT01385228 | Prostate Cancer | Pazopanib Docetaxel Pazopanib Prednisone Pegfilgrastim | 18 Years - | Duke University | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | NCT04821622 | Prostate Cancer | talazoparib plu... Placebo plus en... | 18 Years - | Pfizer | |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | NCT04887506 | Metastatic Cast... Metastatic Cast... Metastatic Pros... | TAVT-45 Zytiga Prednisone | 18 Years - | Tavanta Therapeutics | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer | NCT02260817 | Metastatic Pros... | 11C-choline Inj... | 18 Years - | Global Isotopes, LLC d/b/a Zevacor Molecular | |
| A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | NCT05917470 | Metastatic Cast... | ONCT-534 | 18 Years - | Oncternal Therapeutics, Inc | |
| Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC | NCT03432949 | Metastatic Pros... | Dexamethasone p... | - | University Health Network, Toronto | |
| A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients | NCT06009549 | Metastatic Pros... | 18 Years - | Power Life Sciences Inc. | ||
| PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer | NCT04220983 | Metastatic Pros... | MR-Guided Prost... | 18 Years - 90 Years | Weill Medical College of Cornell University | |
| Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate | NCT05590793 | Advanced Prosta... Metastatic Pros... Locally Advance... | Triptorelin pam... | 18 Years - | Ipsen | |
| 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) | NCT04726033 | Metastatic Pros... | 64Cu-DOTA-TLX59... | - | Telix Pharmaceuticals (Innovations) Pty Limited | |
| Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC | NCT01062503 | Metastatic Pros... Bone Metastasis | Zoledronic acid | 18 Years - | University Health Network, Toronto | |
| Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer | NCT02151760 | Metastatic Pros... | 18F-DCFPyL | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer | NCT06359821 | Metastatic Pros... | ZA-001 | 18 Years - 100 Years | Sichuan University | |
| Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | NCT04846478 | Metastatic Pros... Metastatic Cast... | Talazoparib Tazemetostat | 18 Years - | Dana-Farber Cancer Institute | |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | NCT04038502 | Metastatic Cast... BARD1, BRCA1, B... RAD51B, RAD51C,... | Carboplatin Olaparib | 18 Years - | VA Office of Research and Development | |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | NCT04335682 | Metastatic Pros... Prostate Cancer... Prostate Cancer Castrate Resist... | Darolutamide Enzalutamide | 18 Years - | Alliance Foundation Trials, LLC. | |
| Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer | NCT00441571 | Metastatic Pros... | 177Lu-CYT-500 | 18 Years - | Cytogen Corporation | |
| PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer | NCT04220983 | Metastatic Pros... | MR-Guided Prost... | 18 Years - 90 Years | Weill Medical College of Cornell University | |
| A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease | NCT01933022 | Metastatic Pros... | Eligard | 18 Years - | Astellas Pharma Inc | |
| A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01834209 | Prostate Neopla... | Abiraterone ace... Prednisone or p... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | NCT01981122 | Metastatic Pros... | sipuleucel-T enzalutamide | 18 Years - | Dendreon | |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | NCT05413421 | Metastatic Pros... Neuroendocrine ... | ORIC-944 | 18 Years - | ORIC Pharmaceuticals | |
| Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial | NCT06040125 | PROSTATE CANCER Metastatic Pros... Metastatic Pros... | Supervised Circ... | 18 Years - | Dana-Farber Cancer Institute | |
| Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction | NCT04925648 | Metastatic Pros... | Dasatinib Darolutamide | 18 Years - | St Vincent's Hospital, Sydney | |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | NCT01981122 | Metastatic Pros... | sipuleucel-T enzalutamide | 18 Years - | Dendreon | |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) | NCT03050866 | Circulating Tum... Metastatic Pros... | Cabazitaxel Antihistamine Corticosteroid H2 antagonist Antiemetic | 18 Years - | Erasmus Medical Center | |
| CMAB vs IMAB in Metastatic Prostate Cancer | NCT00255268 | Metastatic Pros... | Goserelin Bicalutamide | 18 Years - | AstraZeneca | |
| A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients | NCT06009549 | Metastatic Pros... | 18 Years - | Power Life Sciences Inc. | ||
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | NCT05189457 | Prostate Cancer Stage IV Prosta... | Luteinizing Hor... New Hormonal Ag... Docetaxel Tislelizumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer | NCT05582772 | Metastatic Pros... | GA+M Interventi... RSM interventio... GA+RSM interven... | 65 Years - | University Health Network, Toronto | |
| Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer | NCT06050239 | Metastatic Pros... | 177Lu-PSMA-0057 | 18 Years - | Nanjing First Hospital, Nanjing Medical University | |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | NCT04887506 | Metastatic Cast... Metastatic Cast... Metastatic Pros... | TAVT-45 Zytiga Prednisone | 18 Years - | Tavanta Therapeutics | |
| A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer | NCT00055471 | Prostatic Neopl... Metastases, Neo... | ZD4054 10 mg ZD4054 15 mg ZD4054 22.5 mg | 18 Years - | AstraZeneca | |
| Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer | NCT04556045 | Metastatic Pros... | Exercise therap... | 18 Years - | Case Comprehensive Cancer Center | |
| TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer | NCT05582772 | Metastatic Pros... | GA+M Interventi... RSM interventio... GA+RSM interven... | 65 Years - | University Health Network, Toronto | |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | NCT04478279 | Glioblastoma Melanoma Stage ... Breast Cancer Prostate Cancer Glioblastoma Mu... GBM Brain Cancer Metastatic Brea... Metastatic Mela... Metastatic Pros... Melanoma Recurr... Prostate Cancer... Recurrent Gliob... Newly Diagnosed... | ST101 Temozolomide Radiation | 18 Years - | Sapience Therapeutics | |
| A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | NCT05917470 | Metastatic Cast... | ONCT-534 | 18 Years - | Oncternal Therapeutics, Inc | |
| Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | NCT02446405 | Prostatic Neopl... | Enzalutamide NSAA LHRHA or Surgic... | 18 Years - | University of Sydney | |
| Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | NCT01815515 | Metastatic Pros... | 18F-DCFBC | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4) | NCT02730338 | Metastatic Pros... | High intensity ... Psychosocial su... | 18 Years - | Movember Foundation | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| Biomarkers of Bone Resorption in Metastatic Prostate Cancer | NCT01233557 | Metastatic Pros... | 40 Years - 80 Years | University of Aberdeen | ||
| Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC | NCT05771896 | Metastatic Pros... | Darolutamide Radium-223 | 18 Years - | GenesisCare USA | |
| A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer | NCT00942578 | Metastatic Pros... | Bevacizumab Lenalidomide Docetaxel Prednisone | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | NCT03248570 | Castration Resi... Metastatic Pros... | Pembrolizumab Chemotherapy | 18 Years - | University of California, San Francisco | |
| A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | NCT01957436 | Metastatic Pros... | abiraterone ace... radiotherapy Androgen Depriv... Docetaxel | 18 Years - | UNICANCER | |
| LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | NCT06303713 | Prostate Cancer Metastatic Pros... Metastatic Cast... | Carboplatin 177Lu-PSMA-617 | 18 Years - | Dana-Farber Cancer Institute | |
| Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) | NCT05404139 | Metastatic Pros... | Enzalutamide Standard of Car... | 18 Years - 100 Years | University Health Network, Toronto | |
| Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer. | NCT03497377 | Metastatic Pros... | 18F-DCFPyL Inje... 18F-NaF | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients | NCT01254513 | Prostate Cancer | Docetaxel every... Docetaxel weekl... | 75 Years - | UNICANCER | |
| A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer | NCT02066961 | Prostate Cancer Castration-resi... Metastatic Pros... | - | Astellas Pharma Inc | ||
| mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer | NCT04545697 | Metastatic Pros... | Medcorder | 18 Years - | University of California, San Francisco | |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | NCT06267729 | Metastatic Pros... | AZD0754 | 18 Years - 130 Years | AstraZeneca | |
| Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer | NCT01923727 | Metastatic Pros... | [89Zr]Df-IAB2M | 18 Years - | ImaginAb, Inc. | |
| Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer | NCT03230734 | Metastatic Cast... | Radium-223 Docetaxel | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) | NCT02380274 | Prostate Cancer Castration-resi... Metastatic Pros... | 18 Years - | Astellas Pharma Inc | ||
| Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC | NCT03432949 | Metastatic Pros... | Dexamethasone p... | - | University Health Network, Toronto | |
| 68Ga-PSMA PET/CT for Ra223 Assessment | NCT04951817 | Metastatic Pros... | Ga-68 PSMA liga... | 40 Years - 85 Years | Chang Gung Memorial Hospital | |
| ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer | NCT00415779 | Metastatic Pros... | docetaxel zoledronic acid | 18 Years - | National Cancer Institute, Naples | |
| Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer | NCT01296139 | Prostate Cancer | Ferumoxytol | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease | NCT01933022 | Metastatic Pros... | Eligard | 18 Years - | Astellas Pharma Inc | |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | NCT05617885 | Metastatic Pros... Non-metastatic ... Prostate Cancer | Darolutamide Abemaciclib GNRH-A Leuproli... GNRH-A Gosereli... Degarelix | 18 Years - | Dana-Farber Cancer Institute | |
| Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) | NCT05404139 | Metastatic Pros... | Enzalutamide Standard of Car... | 18 Years - 100 Years | University Health Network, Toronto | |
| Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | NCT02500901 | Metastatic Pros... | Enzalutamide Niraparib | 18 Years - | Hoosier Cancer Research Network | |
| Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients | NCT01677897 | Metastatic Pros... | Metformin | 18 Years - 90 Years | Kantonsspital Graubünden | |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | NCT05367440 | Metastatic Pros... | AZD5305 Enzalutamide Abiraterone Ace... Darolutamide Apalutamide | 18 Years - 130 Years | AstraZeneca | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients | NCT06350825 | Metastatic Pros... Therapy, Direct... | Cytoreductive p... ADT+second-gene... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
